Categories:
North Dakota Medicaid Drug Use Review Board
Wednesday, June 5, 2024
1 p.m. to 4 p.m. Central Time
In-Person Information
Conference Room 210/212, 2nd Floor, Judicial Wing, State Capitol
600 E. Boulevard Ave., Bismarck
Virtual Information
Join virtually: Click here to join the meeting
Join by phone: 701-328-0950, Conference ID: 876 672 920 #
Agenda
1. Call to Order
2. Roll Call
3. Review and Approval of Minutes
4. Reports from Department
• Administrative Report: Utilization Review
• Financial Report: Top Drugs
• Retrospective DUR Report
• Clinical Report:
o Prior Authorization Update
o Criteria updates: Food Allergy (Xolair), Peanut Allergy (Palfozia), Reduce Risk of Major Adverse Cardiovascular Events (Wegovy), Pulmonary Hypertension (Wenrevair), Tardive Dyskinesia (Ingrezza, Austedo)
5. Special Orders: Presiding Officer and Vice-Presiding Officer Elections
6. Unfinished Business: Update to Hyperkalemia
7. New business
• Second Review of Acid Blockers (Voquezna)
• Second Review of Seborrheic Dermatitis (Zoryve)
• Second Review of Primary Hyperoxaluria Type 1 (Rivfloza)
• Second Review of Myasthenia Gravis (Zilbrysq)
• Second Review of Duchenne Muscular Dystrophy (Emflaza, Agamree)
• Second Review of Paroxysmal Nocturnal Hemoglobinuria (Empaveli, Fabhalta)
• First Review of Molluscum Cantagiosum (Ycanth and Zelsuvmi)
• First Review of Epidermolysis Bullosa (Filsuvez)
• First Review of Metabolic Dysfunction–Associated Steatohepatitis (Rezdiffra)
• Review of retrospective DUR criteria recommendations
8. Announcements: Next Meeting (September 4, 2024)
9. Adjourn
Individuals with disabilities who need accommodations, including appropriate auxiliary aids to participate, can contact Ashley Gerving at 701-328-2354, toll-free 800-755-2604, 711 (TTY) or gervingashley@nd.gov.
Date Posted: Jan. 18, 2024
Date Revised: April 29, 2024 (agenda/meeting details added)